Riskpilot← Back to searchSign inGet full accessLundin Läkarkonsult AB
ABIn liquidationOrg 5591069918General medical practice activities · NACE 8621Est. 20170 employees
Revenue 2023
SEK 0
EBITDA margin
—
-4110% vs 2022
Equity ratio
100.0%
Financial strength
Net profit 2023
SEK -992K
-1205% vs 2022
| Revenue | SEK 0 | — |
| EBITDA | SEK -1,3M | -4110% |
| Net profit | SEK -992K | -1205% |
| Total assets | SEK 388K | -86% |
| Equity | SEK 388K | -72% |
| Employees | 0 | — |
Legal name
Lundin Läkarkonsult AB
Org number
5591069918
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
30 mars 2017
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Firman tecknas ensam av likvidatorn
Company purpose
Bolaget skall tillhandahålla tjänster inom hälso- och sjukvård, och utbildningsverksamhet. Bedriva forsknings- och utvecklingsverksamhet inom hälso- och sjukvård. Bedriva förvaltning och handel av fastigheter, skog, värdepapper, finansiella instrument och ädelmetaller, samt därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenue | 687 | 488 | 251 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 685 | 420 | 161 | −30 | −1 263 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 685 | 420 | 161 | −30 | −1 263 |
| Net financials | −44 | −18 | −2 | −45 | — |
| Profit before tax | 641 | 402 | 159 | −76 | −992 |
| Tax | −140 | −91 | −46 | −0 | −0 |
| Net profit | 501 | 311 | 113 | −76 | −992 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Total assets | 2 724 | 2 568 | 2 306 | 2 738 | 388 |
| Equity | 1 033 | 1 344 | 1 456 | 1 380 | 388 |
| Long-term debt | 825 | 0 | 0 | 0 | 0 |
| Short-term debt | 596 | 954 | 580 | 1 088 | 0 |
| Total debt | 1 421 | 954 | 580 | 1 088 | — |
EBITDA margin
-126300000.0%
This company
15.8%
Market median
-799367189% vs market
20192023
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20192023
Return on equity
-255.7%
This company
18.4%
Market median
-1490% vs market
20192023
Net profit margin
-99200000.0%
This company
8.1%
Market median
-1224691458% vs market
20192023
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20192023
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20192023
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
KP Liquidator | Liquidator | 2022 |
| Name | Role | Member since |
|---|---|---|
| Former (2) | ||
| Deputy Board Member | 2021 – 2022 | |
| Board of Directors | 2021 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Lundin Läkarkonsult AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kari Pentti Olavi Wergens | Liquidator | 0 companies |
| Ulrika Linnea Lundin Glans | Deputy Board Member | 0 companies |
| Eva Ann-Marie Lundin | Board of Directors | 0 companies |